# An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

> **NCT03363776** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 10 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** BMS-986277
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03363776
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-06
- **Primary completion:** 2019-11-22
- **Final completion:** 2019-11-22
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363776, "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03363776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*